Compare StocksABBV vs EXPD

AbbVie Inc. (ABBV) vs Expeditors International of Washington, Inc. (EXPD): Which Is the Better Buy in 2026?

As of 2026-06-19, ABBV is overvalued at $216, with a DCF intrinsic value of $160 and a margin of safety of -35%. EXPD is overvalued at $161, with an intrinsic value of $101 and a margin of safety of -60%. Of the two, ABBV has the wider margin of safety.

ABBV
AbbVie Inc.
$216.49
VS
EXPD
Expeditors International of Washington, Inc.
$161.32

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
EXPD
  • Expeditors International of Washington, Inc. has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • Return on equity has consistently exceeded 20% over 4 years, indicating efficient use of shareholder capital.
  • Share count has been reduced by 13% over the past 4 years through buybacks, increasing each share's claim on earnings.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • FCF yield of 5.4% suggests reasonable valuation assuming continued moderate growth.
  • Trailing P/E of 105.6x is 69% above the historical average of 62.3x — the stock trades at a premium to its own history.
EXPD
  • Gross margin of 13.6% is low, suggesting a competitive or commodity-like market with limited pricing power.
  • Trailing P/E of 26.1x is 28% above the historical average of 20.5x — the stock trades at a premium to its own history.
  • PEG ratio of 3.77 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.

Key Valuation Metrics

Learn more →
ABBV
EXPD
Valuation
$20.81B
Free Cash Flow
$783.25M
5.44%
FCF Yield
3.71%
105.60
Trailing P/E
26.10
13.32
Forward P/E
23.65
Quality & Moat
21.89%
ROIC
32.83%
N/A
ROE
36.64%
72.03%
Gross Margin
13.62%
0.61
PEG Ratio
3.77
Balance Sheet Safety
N/A
Net Debt / Equity
Net cash
N/A
Interest Coverage
N/A
2.12
Net Debt / EBITDA
-0.66
3.11%
Dividend Yield
0.99%
ABBV: 6Ties: 1EXPD: 3
ABBVEXPD

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

EXPD

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
EXPD
$2.22
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$1.76B
Δ Market Cap
+$3.91B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
35.3% Overvalued
Price is 35.3% above estimated fair value
Current Price: $216.49
Fair Value: $160.05
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
EXPD
59.7% Overvalued
Price is 59.7% above estimated fair value
Current Price: $161.32
Fair Value: $101.02
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

What growth rate is the market pricing in at $216?

+17.1%
Market-Implied Owner Earnings Growth
Standard FCF implies +8.7%

The market implies +17.1% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +8.7%, reflecting heavy growth investment.

EXPD

What growth rate is the market pricing in at $161?

+10.7%
Market-Implied Owner Earnings Growth
Standard FCF implies +11.3%

The market implies +10.7% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +11.3%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
EXPD
69/100
Narrow Moat
70+ Wide · 40-69 Narrow · <40 None

Narrow moat with margin stability as the key competitive advantage. Improving revenue predictability would strengthen the moat.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
EXPD
-2.55
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
No. of Institutional Holders5,106
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
EXPD
Insiders 0.6%Institutions 101.0%
No. of Institutional Holders1,297
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
EXPD
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
0
Sells (3M)
5
Sells (12M)
Total value (12M): $21.79M
PURDUE DAVID R.
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
GONZALEZ RICHARD A
Officer and Director
$12.40M
@ $186.52 · 2024-08-05
GONZALEZ RICHARD A
Officer and Director
$49.50M
@ $175.00 · 2024-07-17
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
EXPD
0
Sells (3M)
8
Sells (12M)
Total value (12M): $6.40M
WALL DANIEL R.
Chief Executive Officer
$884,927
@ $145.07 · 2026-02-27
BELL BLAKE R
Officer
$1.49M
@ $144.08 · 2026-02-27
EMMERT MARK A
Director
$730,350
@ $135.25 · 2025-11-07
DICKERMAN JEFFREY F
General Counsel
$201,255
@ $134.17 · 2025-11-05
CARLILE ROBERT PAUL
Director
$301,268
@ $120.51 · 2025-09-05
EMMERT MARK A
Director
$497,150
@ $121.26 · 2025-08-19
DICKERMAN JEFFREY F
General Counsel
$173,535
@ $118.05 · 2025-08-07
BELL BLAKE R
Officer
$2.12M
@ $117.89 · 2025-08-06
WALL DANIEL R.
Chief Executive Officer
$1.16M
@ $115.91 · 2025-05-12
DICKERMAN JEFFREY F
General Counsel
$146,923
@ $117.54 · 2025-02-20
CARLILE ROBERT PAUL
Director
$363,332
@ $121.11 · 2024-12-10
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😐Neutral(56/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
EXPD
FearGreed
😏Greed(64/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (56)
EXPD
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (64)
View ABBV Full AnalysisView EXPD Full Analysis

Frequently Asked Questions: ABBV vs EXPD

Is AbbVie Inc. or Expeditors International of Washington, Inc. more undervalued in 2026?

Based on our discounted cash flow model, ABBV trades at a -35.3% margin of safety (intrinsic value $160 vs. price $216), compared to EXPD's -59.7% margin of safety (intrinsic $101 vs. $161).

Which stock has a wider economic moat, AbbVie Inc. or Expeditors International of Washington, Inc.?

ABBV scores 82/100 (Wide moat), while EXPD scores 69/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. EXPD scores 8.8 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which company has better free cash flow, AbbVie Inc. or Expeditors International of Washington, Inc.?

AbbVie Inc. (ABBV) generates a 5.4% free cash flow yield, compared to Expeditors International of Washington, Inc.'s 3.7%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, AbbVie Inc. or Expeditors International of Washington, Inc.?

EXPD earns 32.8% ROIC versus ABBV's 21.9%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or Expeditors International of Washington, Inc.'s?

EXPD's dividend earns a safety score of 94/100 (Very Safe), compared to ABBV's 39/100 (Unsafe). EXPD has raised its dividend for 3 consecutive years.